UroGen Pharma Ltd (NASDAQ: URGN) on Friday, soared 5.28% from the previous trading day, before settling in for the closing price of $18.0. Within the past 52 weeks, URGN’s price has moved between $3.42 and $19.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 10.39%. The company achieved an average annual earnings per share of 1.54%. With a float of $39.70 million, this company’s outstanding shares have now reached $46.10 million.
Let’s determine the extent of company efficiency that accounts for 235 employees. In terms of profitability, gross margin is 89.68%, operating margin of -117.51%, and the pretax margin is -147.23%.
UroGen Pharma Ltd (URGN) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of UroGen Pharma Ltd is 14.08%, while institutional ownership is 96.70%. The most recent insider transaction that took place on Jun 09 ’25, was worth 38,044. In this transaction Chief Medical Officer of this company sold 5,162 shares at a rate of $7.37, taking the stock ownership to the 153,378 shares. Before that another transaction happened on Jun 09 ’25, when Company’s Officer proposed sale 5,162 for $7.37, making the entire transaction worth $38,044.
UroGen Pharma Ltd (URGN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 1.54% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
UroGen Pharma Ltd (URGN) is currently performing well based on its current performance indicators. A quick ratio of 5.47 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.18, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -1.09 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
Looking closely at UroGen Pharma Ltd (NASDAQ: URGN), its last 5-days average volume was 1.86 million, which is a jump from its year-to-date volume of 1.62 million. As of the previous 9 days, the stock’s Stochastic %D was 88.56%.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 98.73%, which indicates a significant increase from 96.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.05 in the past 14 days, which was higher than the 0.94 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.06, while its 200-day Moving Average is $11.11. However, in the short run, UroGen Pharma Ltd’s stock first resistance to watch stands at $19.41. Second resistance stands at $19.86. The third major resistance level sits at $20.73. If the price goes on to break the first support level at $18.09, it is likely to go to the next support level at $17.22. Should the price break the second support level, the third support level stands at $16.77.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
Market capitalization of the company is 875.52 million based on 46,201K outstanding shares. Right now, sales total 90,400 K and income totals -126,870 K. The company made 20,250 K in profit during its latest quarter, and -43,840 K in sales during its previous quarter.
